Patents Examined by Robert H Havlin
  • Patent number: 11474111
    Abstract: Characterization of the binding dynamics at the interface between any two proteins that specifically interact plays a role in myriad biomedical applications. The methods disclosed herein provide for the high-throughput characterization of the specific interaction at the interface between two protein binding partners and the identification of functionally significant mutations of one or both protein binding partners. For example, the methods disclosed herein may be useful for epitope and paratope mapping of an antibody-antigen pair, which is useful for the discovery and development of novel therapies, vaccines, diagnostics, among other biomedical applications.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: October 18, 2022
    Assignee: A-Alpha Bio, Inc. et al
    Inventors: David Younger, David Colby, Randolph Lopez, Michael Wittekind
  • Patent number: 11459336
    Abstract: Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: October 4, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventor: Christine Gelin
  • Patent number: 11458139
    Abstract: The present technology relates to compositions comprising BRAF inhibitors and uses thereof for treating and/or preventing a MEK inhibitor-associated cutaneous condition in a subject. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: October 4, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Neal Rosen, Noa Shelach
  • Patent number: 11458119
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: October 4, 2022
    Assignee: GENZYME CORPORATION
    Inventors: Hanlan Liu, Chris Willis, Renu Bhardwaj, Jianmei Kochling, Craig Siegel
  • Patent number: 11447503
    Abstract: Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: September 20, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christine Gelin, Heather Coate, Brice Stenne, Curt Dvorak
  • Patent number: 11420961
    Abstract: The invention provides new heterocyclic compounds having the general formula (IA) wherein A, L, X, Y, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: August 23, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Uwe Grether, Benoit Hornsperger, Buelent Kocer, Bernd Kuhn, Hans Richter, Satoshi Tsuchiya, Charles Bell, Xiang Wu, Xiaofei Yan, Luca Gobbi
  • Patent number: 11419946
    Abstract: A heterobifunctional monodispersed polyethylene glycol represented by formula (1) which has two adjacent monodispersed polyethylene glycol side chains and does not have a chiral center in the molecular structure: wherein X1 and Y1 are each an atomic group containing a functional group capable of forming a covalent bond upon a reaction with a functional group present in a biofunctional molecule. R1 is a hydrocarbon group or the like. n is an integer of 3 to 72. A1 represents -L1-(CH2)m1— or the like, L1 and L2 represent each an ether bond or the like, and m1 and m2 each independently represent an integer of 1 to 5. B1 represents -L3-(CH2)m3— or the like, L3 and L4 represent an amide bond or the like, and m3 and m4 each independently represent an integer of 1 to 5. Also disclosed is an antibody-drug conjugate including the heterobifunctional monodispersed polyethylene glycol.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: August 23, 2022
    Assignee: NOF CORPORATION
    Inventors: Takuma Tsubusaki, Kohei Yoshimura, Mika Hamura
  • Patent number: 11414686
    Abstract: This disclosure describes a method of purifying several full-length oligonucleotide targets from corresponding synthesis truncation products, in a way that ensures roughly stoichiometric equality among the targets.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 16, 2022
    Assignee: William Marsh Rice University
    Inventors: David Zhang, Alessandro Pinto
  • Patent number: 11414696
    Abstract: The present disclosure provides a microarray comprising a plurality of probes. Each probe comprises a first oligonucleotide and a second oligonucleotide. The location of each probe on the microarray can be determined by the length of the first oligonucleotide and the length of the second oligonucleotide, thus providing a spatially barcoded microarray. Also provided are the methods of producing such spatially barcoded microarray. Also provided are the method of using such spatially barcoded microarray.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: August 16, 2022
    Assignee: WELLSIM BIOMEDICAL TECHNOLOGIES, INC.
    Inventor: Yuchao Chen
  • Patent number: 11395822
    Abstract: The present description relates to a method or use of a compound for treating or ameliorating HD (Huntington's Disease) in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): or a form thereof, wherein R1, R2, Ra, Rb and Rc are as defined herein. In particular, the present description relates to a method of use of a compound of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering an effective amount of the compound or a form or composition thereof to the subject.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: July 26, 2022
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Anuradha Bhattacharyya, Minakshi B. Jani
  • Patent number: 11396650
    Abstract: The invention provides compositions comprising nucleic acid complexes for use in screening compounds based on their ability to modulate binding interactions, wherein the compounds are barcoded.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: July 26, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Wesley Philip Wong, Clinton H. Hansen
  • Patent number: 11365408
    Abstract: The disclosure provides DNA library preparation methods that do not require a purification between adapter ligation and PCR amplification. Adaptors are added to DNA fragments to form oligonucleotide extension products and the oligonucleotide extension products are amplified without stopping or interruption for a cleanup step. Excess materials, such as enzymes, adaptors, or co-factors, from the adaptor addition step do not interfere with the amplification step and the amplification step proceeds without regards to the presence of reagents from the ligation step. In preferred embodiments, the ligation and amplification step make use of a common priming sequence e.g., in the form of one of the adaptor oligos.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: June 21, 2022
    Assignee: NUGEN TECHNOLOGIES, INC.
    Inventors: Bin Li, Benjamin G. Schroeder, Manqing Hong, Maureen Peterson
  • Patent number: 11364246
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: June 21, 2022
    Assignee: TMEM16A LIMITED
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • Patent number: 11339124
    Abstract: The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxytosis for the treatment of stroke, myocardial infarction, diabetes, sepsis, the prevention of transplant rejection, neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, dementia with Lewy bodies and Friedreich's ataxia. The present invention further relates to pharmaceutical compositions of these compounds and discloses methods for making the compounds and the corresponding intermediate.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: May 24, 2022
    Assignees: UNIVERSITEIT ANTWERPEN, VIB VZW, UNIVERSITEIT GENT
    Inventors: Peter Vandenabeele, Tom Vanden Berghe, Koen Augustyns, Sam Hofmans, Pieter Van Der Veken, Lars Devisscher
  • Patent number: 11339141
    Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 24, 2022
    Assignee: PMV Pharmaceuticals, Inc.
    Inventors: Binh Vu, Romyr Dominique, Hongju Li
  • Patent number: 11339391
    Abstract: The invention provides a method for efficient DNA library construction and targeted genetic analyses of the libraries.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 24, 2022
    Assignee: Resolution Bioscience, Inc.
    Inventors: Christopher K. Raymond, Lee P. Lim
  • Patent number: 11319594
    Abstract: The present invention includes compositions and methods useful for the detection of a mutational change, SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: May 3, 2022
    Assignee: Resolution Bioscience, Inc.
    Inventors: Christopher Raymond, Lee Lim, Jennifer Hernandez
  • Patent number: 11299635
    Abstract: This invention relates to bis-azo colorants for use as bluing agents, laundry care compositions comprising bis-azo colorants that may serve as bluing agents, processes for making such bluing agents and laundry care compositions and methods of using the same. The bluing agents are generally comprised of at least two components: at least one chromophore component and at least one polymeric component. These bluing agents are advantageous in providing a whitening effect to fabrics, while not building up over time and causing undesirable blue discoloration to the treated fabrics.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 12, 2022
    Assignee: Milliken & Company
    Inventors: Robert L Mahaffey, Jr., Xiaoyong Michael Hong, Eduardo Torres, Dominick J Valenti, Gregory Scot Miracle
  • Patent number: 11279927
    Abstract: Provided herein are compositions, kits and methods for the production of strand-specific cDNA libraries. The compositions, kits and methods utilize properties of double stranded polynucleotides, such as RNA-cDNA duplexes to capture and incorporate a novel sequencing adapter. The methods are useful transcriptome profiling by massive parallel sequence, such as full-length RNA sequencing (RNA-Seq) and 3? tag digital gene expression (DGE).
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: March 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Brad Townsley, Michael F. Covington, Neelima Sinha
  • Patent number: 11274344
    Abstract: Methods for preparing a sequencing library from a DNA-containing test sample are provided. In some embodiments, the methods involve rescuing a partially ligated DNA fragment to enhance library preparation conversion efficiencies. In some embodiments, the methods involve improving recovery of duplex sequence information from double-stranded DNA.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 15, 2022
    Assignee: GRAIL, Inc.
    Inventors: Craig Betts, Byoungsok Jung